Related Experiment Video

Updated: May 27, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling

Dirk Spitzer1, Peter O Simon, Hiroyuki Kashiwagi

  • 1Department of Surgery, Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA.

Cancer Research
|November 9, 2011
PubMed

Insights

Researchers developed a novel platform using σ-2 receptor ligands to selectively deliver cancer drugs. This approach enhances drug efficacy by combining targeted delivery with synergistic cell death pathways for pancreatic cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Selective drug delivery remains a challenge in cancer therapeutics.
  • The σ-2 receptor is a promising target in pancreatic cancer, inducing apoptosis upon activation.
  • Previous work established high-affinity σ-2 receptor ligands, including SV119, which targets pancreatic cancer cells.

Purpose of the Study:

  • To evaluate SV119's potential for delivering additional cytotoxic agents.
  • To determine if conjugation enhances the anti-cancer properties of SV119.
  • To establish a platform for synergistic cancer therapy.

Main Methods:

  • Conjugation of small molecule inhibitors of prosurvival pathways to the SV119 ligand.
  • In vitro and in vivo assessment of the cytotoxic effects of conjugated SV119.
  • Evaluation of the combined efficacy of SV119 and its conjugated cargo.

Main Results:

  • Conjugated small molecules retained their cell death-inducing capabilities.
  • SV119 effectively delivered conjugated therapeutics to pancreatic cancer cells.
  • Combined therapy demonstrated enhanced cytotoxicity compared to SV119 alone, indicating synergistic effects.

Conclusions:

  • SV119 serves as an effective platform for targeted delivery of therapeutics.
  • This strategy enables synergistic cancer therapy by combining σ-2 receptor targeting with inhibition of prosurvival pathways.
  • The findings support a new approach to optimize efficacy and patient benefit in pancreatic cancer treatment.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...